Aprea Therapeutics Files 8-K

Ticker: APRE · Form: 8-K · Filed: Apr 10, 2024 · CIK: 1781983

Aprea Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAprea Therapeutics, Inc. (APRE)
Form Type8-K
Filed DateApr 10, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, filing, financials

Related Tickers: APRE

TL;DR

APRE filed an 8-K on 4/10/24, likely containing operational or financial updates.

AI Summary

On April 10, 2024, Aprea Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new events were detailed in the provided excerpt.

Why It Matters

This filing signals an update from Aprea Therapeutics to the SEC, which could contain material information for investors regarding the company's operations or financial health.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative events or financial distress.

Key Players & Entities

  • Aprea Therapeutics, Inc. (company) — Registrant
  • 0001558370-24-004927 (other) — Accession Number
  • 20240410 (date) — Filing Date
  • 3805 Old Easton Road (other) — Principal Executive Office Address
  • Doylestown, PA (location) — Principal Executive Office Location
  • 18902 (other) — Zip Code
  • ( 617 ) 463-9385 (other) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing by Aprea Therapeutics?

The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences.

When was this 8-K filing submitted to the SEC?

The filing was submitted on April 10, 2024.

What is Aprea Therapeutics' principal executive office address?

The principal executive offices are located at 3805 Old Easton Road, Doylestown, PA 18902.

What is the Commission File Number for Aprea Therapeutics?

The Commission File Number for Aprea Therapeutics is 001-39069.

Does the provided excerpt detail any specific new events or financial figures?

No, the provided excerpt does not detail any specific new events or financial figures.

Filing Stats: 481 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-04-10 16:15:25

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share APRE The Nasdaq Stock Mar

Filing Documents

01 Other Events

Item 8.01 Other Events. On April 10, 2024, Aprea Therapeutics, Inc. (the "Company") issued a press release which provided details about four poster presentations the Company plans to present at the ongoing American Association of Cancer Research (AACR) Annual Meeting. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference. On April 10, 2024, the Company updated its corporate presentation slide deck. A copy of the corporate presentation slide deck is filed as Exhibit 99.2 hereto and incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release issued by Aprea Therapeutics, Inc. dated April 10, 2024. 99.2 Corporate Presentation (April 2024). 104 Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aprea Therapeutics, Inc. Dated: April 10, 2024 By: /s/ Oren Gilad Name: Oren Gilad, Ph.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.